Scholz et al. were the first to show that, in addition to an upregulation in HCC tissue, Ang-2 levels are also elevated in the blood of HCC patients, leading to its potential as a serum biomarker for HCC. Here, ANGPT2 is linked to hepatocellular carcinoma.